• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

建立并验证了一种 UPLC-MS/MS 方法,用于尿液中一线抗结核药物的治疗药物监测、药代动力学和稳定性研究。

Development and Validation of a UPLC-MS/MS Method for Therapeutic Drug Monitoring, Pharmacokinetic and Stability Studies of First-Line Antituberculosis Drugs in Urine.

机构信息

Department of Physical Pharmacy and Pharmacokinetics, Poznan University of Medical Sciences, 3 Rokietnicka Street, 60-806 Poznań, Poland.

Doctoral School, Poznan University of Medical Sciences, 70 Bukowska Street, 60-812 Poznań, Poland.

出版信息

Molecules. 2024 Jan 9;29(2):337. doi: 10.3390/molecules29020337.

DOI:10.3390/molecules29020337
PMID:38257250
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC10818978/
Abstract

Tuberculosis (TB) remains one of the leading global causes of mortality. Several methods have been established to detect anti-TB agents in human plasma and serum. However, there is a notable absence of studies analyzing TB drugs in urine. Thus, our objective was to validate a method for quantifying first-line anti-TB agents: isoniazid (INH), pyrazinamide (PZA), ethambutol (ETH), and rifampicin (RIF), along with its metabolite 25-desacetylrifampicin, and degradation products: rifampicin quinone and 3-formyl-rifampicin in 10 µL of urine. Chromatographic separation was achieved using a Kinetex Polar C18 analytical column with gradient elution (5 mM ammonium acetate and acetonitrile with 0.1% formic acid). Mass spectrometry detection was carried out using a triple-quadrupole tandem mass spectrometer operating in positive ion mode. The lower limit of quantification (LLOQ) was 0.5 µg/mL for INH, PZA, ETH, and RIF, and 0.1 µg/mL for RIF's metabolites and degradation products. The method was validated following FDA guidance criteria and successfully applied to the analysis of the studied compounds in urine of TB patients. Additionally, we conducted a stability study of the anti-TB agents under various pH and temperature conditions to mimic the urine collection process in different settings (peripheral clinics or central laboratories).

摘要

结核病 (TB) 仍然是全球主要的死亡原因之一。已经建立了几种方法来检测人血浆和血清中的抗结核药物。然而,分析尿液中 TB 药物的研究却明显缺乏。因此,我们的目标是验证一种定量分析一线抗结核药物的方法:异烟肼 (INH)、吡嗪酰胺 (PZA)、乙胺丁醇 (ETH) 和利福平 (RIF),以及其代谢物 25-脱乙酰利福平,以及降解产物:利福平醌和 3-甲酰基利福平,检测量为 10 μL 尿液。采用 Kinetex Polar C18 分析柱进行梯度洗脱(5 mM 乙酸铵和乙腈,含 0.1%甲酸)实现色谱分离。采用三重四极杆串联质谱仪在正离子模式下进行质谱检测。INH、PZA、ETH 和 RIF 的定量下限 (LLOQ) 为 0.5 μg/mL,RIF 代谢物和降解产物的 LLOQ 为 0.1 μg/mL。该方法遵循 FDA 指导原则进行了验证,并成功应用于 TB 患者尿液中研究化合物的分析。此外,我们还进行了抗结核药物在不同 pH 值和温度条件下的稳定性研究,以模拟不同环境(周边诊所或中心实验室)中尿液采集过程。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/da12/10818978/aa81a1e265b8/molecules-29-00337-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/da12/10818978/3025517764ef/molecules-29-00337-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/da12/10818978/e9d8cf1e8603/molecules-29-00337-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/da12/10818978/aa81a1e265b8/molecules-29-00337-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/da12/10818978/3025517764ef/molecules-29-00337-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/da12/10818978/e9d8cf1e8603/molecules-29-00337-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/da12/10818978/aa81a1e265b8/molecules-29-00337-g003.jpg

相似文献

1
Development and Validation of a UPLC-MS/MS Method for Therapeutic Drug Monitoring, Pharmacokinetic and Stability Studies of First-Line Antituberculosis Drugs in Urine.建立并验证了一种 UPLC-MS/MS 方法,用于尿液中一线抗结核药物的治疗药物监测、药代动力学和稳定性研究。
Molecules. 2024 Jan 9;29(2):337. doi: 10.3390/molecules29020337.
2
New approach to rifampicin stability and first-line anti-tubercular drug pharmacokinetics by UPLC-MS/MS.UPLC-MS/MS 法研究利福平稳定性及一线抗结核药物药代动力学
J Pharm Biomed Anal. 2023 Oct 25;235:115650. doi: 10.1016/j.jpba.2023.115650. Epub 2023 Aug 15.
3
Standardization and validation of a novel UPLC-MS/MS method to quantify first line anti-tuberculosis drugs in plasma and dried blood spots.建立和验证一种新型 UPLC-MS/MS 方法,用于定量检测血浆和干血斑中一线抗结核药物。
J Chromatogr B Analyt Technol Biomed Life Sci. 2023 Aug 1;1228:123801. doi: 10.1016/j.jchromb.2023.123801. Epub 2023 Jun 28.
4
Rapid and simultaneous determination of ten anti-tuberculosis drugs in human plasma by UPLC-MS/MS with applications in therapeutic drug monitoring.UPLC-MS/MS 法快速同时测定人血浆中十种抗结核药物及其在治疗药物监测中的应用。
J Chromatogr B Analyt Technol Biomed Life Sci. 2020 Sep 1;1152:122246. doi: 10.1016/j.jchromb.2020.122246. Epub 2020 Jun 13.
5
Simultaneous quantification of isoniazid, rifampicin, ethambutol and pyrazinamide by liquid chromatography/tandem mass spectrometry.液相色谱/串联质谱法同时定量测定异烟肼、利福平、乙胺丁醇和吡嗪酰胺
APMIS. 2016 Nov;124(11):1004-1015. doi: 10.1111/apm.12590. Epub 2016 Aug 22.
6
LC-MS/MS method for simultaneous quantification of the first-line anti-tuberculosis drugs and six primary metabolites in patient plasma: Implications for therapeutic drug monitoring.LC-MS/MS 法同时测定患者血浆中一线抗结核药物及其 6 种主要代谢物:治疗药物监测的意义。
J Chromatogr B Analyt Technol Biomed Life Sci. 2021 Nov 15;1185:122986. doi: 10.1016/j.jchromb.2021.122986. Epub 2021 Oct 14.
7
Simultaneous determination of first-line anti-tuberculosis drugs and one metabolite of isoniazid by liquid chromatography/tandem mass spectrometry in patients with human immunodeficiency virus-tuberculosis coinfection.采用液相色谱/串联质谱法同时测定人类免疫缺陷病毒合并肺结核患者一线抗结核药物及异烟肼的一种代谢物
Heliyon. 2021 Jul 9;7(7):e07532. doi: 10.1016/j.heliyon.2021.e07532. eCollection 2021 Jul.
8
Rapid and highly sensitive quantification of the anti-tuberculosis agents isoniazid, ethambutol, pyrazinamide, rifampicin and rifabutin in human plasma by UPLC-MS/MS.采用 UPLC-MS/MS 法快速、灵敏地定量检测人血浆中的抗结核药物异烟肼、乙胺丁醇、吡嗪酰胺、利福平、利福布汀。
J Pharm Biomed Anal. 2020 Feb 20;180:113076. doi: 10.1016/j.jpba.2019.113076. Epub 2019 Dec 26.
9
Rapid and sensitive method for simultaneous determination of first-line anti-tuberculosis drugs in human plasma by HPLC-MS/MS: Application to therapeutic drug monitoring.高效液相色谱-串联质谱法同时测定人血浆中一线抗结核药物的快速灵敏方法:在治疗药物监测中的应用
Tuberculosis (Edinb). 2018 Mar;109:28-34. doi: 10.1016/j.tube.2017.11.012. Epub 2017 Nov 24.
10
Development and validation of a hydrophilic interaction liquid chromatography-tandem mass spectrometry method for the simultaneous determination of five first-line antituberculosis drugs in plasma.建立并验证一种亲水作用色谱-串联质谱法,用于同时测定血浆中五种一线抗结核药物。
Anal Bioanal Chem. 2013 Jul;405(19):6323-35. doi: 10.1007/s00216-013-7049-0. Epub 2013 May 30.

引用本文的文献

1
Formulation of Topical Drug Delivery Systems Containing a Fixed-Dose Isoniazid-Rifampicin Combination Using the Self-Emulsification Mechanism.利用自乳化机制制备含固定剂量异烟肼-利福平组合的局部给药系统
Pharmaceutics. 2025 May 22;17(6):680. doi: 10.3390/pharmaceutics17060680.

本文引用的文献

1
Four-Month High-Dose Rifampicin Regimens for Pulmonary Tuberculosis.四个月高剂量利福平方案治疗肺结核。
NEJM Evid. 2023 Sep;2(9):EVIDoa2300054. doi: 10.1056/EVIDoa2300054. Epub 2023 Aug 22.
2
Simplified urine-based method to detect rifampin underexposure in adults with tuberculosis: a prospective diagnostic accuracy study.基于简化尿液的方法检测结核病成人中利福平剂量不足:一项前瞻性诊断准确性研究。
Antimicrob Agents Chemother. 2023 Nov 15;67(11):e0093223. doi: 10.1128/aac.00932-23. Epub 2023 Oct 25.
3
New approach to rifampicin stability and first-line anti-tubercular drug pharmacokinetics by UPLC-MS/MS.
UPLC-MS/MS 法研究利福平稳定性及一线抗结核药物药代动力学
J Pharm Biomed Anal. 2023 Oct 25;235:115650. doi: 10.1016/j.jpba.2023.115650. Epub 2023 Aug 15.
4
Rifampin urinary excretion to predict serum targets in children with tuberculosis: a prospective diagnostic accuracy study.利福平尿排泄预测结核病儿童的血清靶标:一项前瞻性诊断准确性研究。
Arch Dis Child. 2023 Aug;108(8):616-621. doi: 10.1136/archdischild-2022-325250. Epub 2023 Apr 25.
5
Alternative Methods for Therapeutic Drug Monitoring and Dose Adjustment of Tuberculosis Treatment in Clinical Settings: A Systematic Review.临床环境中治疗结核病的治疗药物监测和剂量调整的替代方法:系统评价。
Clin Pharmacokinet. 2023 Mar;62(3):375-398. doi: 10.1007/s40262-023-01220-y. Epub 2023 Mar 4.
6
High dose rifampin for 2 months vs standard dose rifampin for 4 months, to treat TB infection: Protocol of a 3-arm randomized trial (2R2).高剂量利福平治疗 2 个月与标准剂量利福平治疗 4 个月治疗结核感染:一项 3 臂随机试验方案(2R2)。
PLoS One. 2023 Feb 2;18(2):e0278087. doi: 10.1371/journal.pone.0278087. eCollection 2023.
7
Safety of Rifampicin at High Dose for Difficult-to-Treat Tuberculosis: Protocol for RIAlta Phase 2b/c Trial.高剂量利福平治疗难治性结核病的安全性:RIAlta 2b/c期试验方案
Pharmaceutics. 2022 Dec 20;15(1):9. doi: 10.3390/pharmaceutics15010009.
8
A high-throughput LC-MS/MS method for simultaneous determination of isoniazid, ethambutol and pyrazinamide in human plasma.一种用于同时测定人血浆中异烟肼、乙胺丁醇和吡嗪酰胺的高通量 LC-MS/MS 方法。
Rapid Commun Mass Spectrom. 2023 Jan 30;37(2):e9425. doi: 10.1002/rcm.9425.
9
Mass spectrometry for therapeutic drug monitoring of anti-tuberculosis drugs.用于抗结核药物治疗药物监测的质谱分析
Clin Mass Spectrom. 2018 Oct 19;14 Pt A:34-45. doi: 10.1016/j.clinms.2018.10.002. eCollection 2019 Sep.
10
LC-MS/MS method for simultaneous quantification of the first-line anti-tuberculosis drugs and six primary metabolites in patient plasma: Implications for therapeutic drug monitoring.LC-MS/MS 法同时测定患者血浆中一线抗结核药物及其 6 种主要代谢物:治疗药物监测的意义。
J Chromatogr B Analyt Technol Biomed Life Sci. 2021 Nov 15;1185:122986. doi: 10.1016/j.jchromb.2021.122986. Epub 2021 Oct 14.